Denosumab safer than romosozumab in terms of cardiovascular outcomes
Denosumab appears to have a neutral effect on the risk of composite and specific cardiovascular outcomes among patients with primary osteoporosis, whereas romosozumab may contribute to an increased risk of four-point major adverse cardiovascular event, according to the results of a meta-analysis.